The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer ...
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...
The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback